Search clinical trials for: keyhole-limpet hemocyanin

Total 240 results

Ensoma
bluebird bio

Terminated

Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

Sickle Cell Disease

United States
UCB Biopharma S.P.R.L.

No longer available

Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures

Epilepsies, Partial
UCB BIOSCIENCES, Inc.

Completed

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures (ALEX-MT)

Epilepsy

Austria, United States, Australia, Canada, Denmark, France, Germany, Ireland, Italy, Poland, Puerto Rico, Spain, United Kingdom
Chulalongkorn University
Sanpasitthiprasong Hospital; Burapha University

Completed

Lime Powder Regimen (LPR) for Prevention of Renal Stone Recurrence

Urolithiasis

Thailand
Boston Children's Hospital

Withdrawn

Trial of Computerized MET for Adolescent Substance Use

Nicotine Dependence | Drug Abuse | Alcohol Abuse

United States
Aarhus University Hospital Skejby

Completed

Procalcitonin as a Marker of Bacterial Pneumonia

Pneumonia | Bronchitis | COPD

Denmark
UCB Pharma

Completed

Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

Epilepsy

United States, Australia, Canada, Denmark, Germany, Italy, Poland, United Kingdom, Spain
UCB Pharma

Completed

Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure (SELF)

Partial Epilepsies

France
UCB BIOSCIENCES, Inc.

Completed

Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. (ASPIRE)

Epilepsy

United States, Hungary, Italy, Poland, Ukraine
UCB BIOSCIENCES, Inc.
UCB Biopharma SRL

Completed

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, China, Colombia, Croatia, Czechia, Estonia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Monten... and more
UCB Pharma

Completed

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

Fibromyalgia Syndrome

United States
UCB BIOSCIENCES, Inc.

Completed

Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Epilepsy

United States
Universidad Peruana Cayetano Heredia
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis

Fascioliasis
UCB Pharma

Completed

Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.

Painful Diabetic Neuropathy

Russian Federation, Austria, Belgium, Bulgaria, Czechia, Finland, France, Germany, Hungary, Italy, Poland, Romania, Serbia, Spain, United Kingdom
Le Bonheur Children's Hospital

Completed

The Safety of Intravenous Lacosamide

Epilepsy

United States
Le Bonheur Children's Hospital

Completed

IV Lacosamide: The Safety of Intravenous Lacosamide

Epilepsy

United States
UCB Pharma

Completed

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Epilepsy

United States, Belgium, Mexico
UCB Pharma

Completed

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Partial Epilepsies

United States, Poland, United Kingdom, Switzerland, Hungary, Germany, Sweden, Lithuania
UCB Pharma

Completed

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Partial Epilepsies

United States, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Italy, Mexico, Romania, Russian Federation, Spain, Switzerland, Turkey
UCB BIOSCIENCES, Inc.

Completed

Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

Partial Epilepsies | Partial Onset Seizures

United States
Lawson Health Research Institute
UCB Pharma GmbH

Terminated

Lacosamide IV and EEG/EKG (LIVE) Study (LIVE)

Focal Epilepsy

Canada
UCB Pharma

Completed

Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures (PASS)

Epilepsies, Partial

France, Germany, United Kingdom, Spain, Netherlands
UCB Pharma

Completed

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis (SP906)

Migraine

United States
UCB Pharma

Completed

Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older

Seizures

Belgium
UCB BIOSCIENCES, Inc.

Completed

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Epilepsy

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

Systemic Lupus Erythematosus (SLE) | ANCA Associated Vasculitis (AAV) | Idiopathic Inflammatory Myopathy (IIM)

China
Indiana University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis (STTEPP)

Chronic Pain | Opioid-Related Disorders | Opioid Use Disorder | Opioid Dependence | Chronic Pancreatitis | Hyperalgesia | Chronic Pain Syndrome | ERCP | Pancreatic Surgery | Chronic Abdominal Pain

United States
UCB BIOSCIENCES, Inc.

Completed

An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy

Epilepsy

United States, Belgium, China, France, Germany, Hungary, Italy, Japan, Mexico, Poland, Ukraine
UCB Pharma GmbH

Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy (VICTOS)

Focal Epilepsy With and Without Secondary Generalization

Germany, Austria
UCB Pharma

Completed

To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects

Epilepsy
AUM Biosciences Pte Ltd
Merck Sharp & Dohme LLC

Recruiting

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Australia
UCB Pharma

Terminated

Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee

Osteoarthritis

Poland, Germany, Romania, Hungary, United Kingdom, Sweden, Czechia
UCB Pharma

Completed

A Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy

Painful Diabetic Neuropathy
Instituto de Investigacion Sanitaria La Fe

Completed

Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication

Epilepsy

Spain
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Diabetes Mellitus, Type 2 | Renal Insufficiency

United States, Canada, France, Hong Kong, India, Malaysia, Netherlands, Philippines, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, United Kingdom
UCB Pharma

Completed

An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

Chronic Refractory Neuropathic Pain

Germany
UCB BIOSCIENCES GmbH

Completed

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects

Healthy | Renal Impairment

Germany
UCB Pharma

Completed

An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy

Painful Diabetic Neuropathy
UCB Pharma

Completed

Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Bulgaria, Colombia, Croatia, Czechia, Estonia, Georgia, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Montenegro, Poland, Romania, Russian Federation, Serbia, Sl... and more
UCB Pharma

Completed

Effect of Lacosamide 200 mg Twice a Day (Bid) on Single Dose Warfarin 25 mg in Healthy Males

Healthy Volunteers

Netherlands
Leiden University Medical Center
HollandPTC

Terminated

Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck (ERM-PT-HNSCC)

Squamous Cell Carcinoma of the Head and Neck

Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

Ependymoma | Anaplastic Ependymoma

United States
Academisch Ziekenhuis Maastricht

Completed

Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy

Small Fiber Neuropathy

Netherlands
Northwestern University
Ann & Robert H Lurie Children's Hospital of Chicago

Completed

Study of Alwextin® Cream in Treating Epidermolysis Bullosa

Epidermolysis Bullosa

United States
UCB Pharma SA

Completed

Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects

Healthy Volunteers

United Kingdom
UCB Pharma SA
UCB Japan Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

China, Japan
Brigham and Women's Hospital

Completed

Add on Lacosamide Versus High Dose Monotherapy

Epilepsy

United States
University of Alabama at Birmingham
UCB Pharma

Terminated

A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide

Traumatic Brain Injury

United States
UCB Pharma

Completed

A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).

Postherpetic Neuralgia
UCB Pharma

Completed

eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam (VERVE)

Epilepsy

United States, Australia, Bulgaria, Denmark, France, Germany, Romania, Spain, Sweden

Search clinical trials for: keyhole-limpet hemocyanin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations